{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:19:14Z","timestamp":1790957954058,"version":"4.1.0"},"reference-count":111,"publisher":"Oxford University Press (OUP)","issue":"s70","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3926,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1111\/j.1365-2133.2004.06269.x","type":"journal-article","created":{"date-parts":[[2004,11,17]],"date-time":"2004-11-17T11:33:25Z","timestamp":1100691205000},"page":"3-27","source":"Crossref","is-referenced-by-count":84,"title":["The role of topical calcineurin inhibitors in atopic dermatitis:"],"prefix":"10.1093","volume":"151","author":[{"given":"A.","family":"Alomar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Berth-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Giannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Reitamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ruzicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-F.","family":"Stalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Thestrup-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"(EUROPEAN WORKING GROUP ON ATOPIC DERMATITIS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"b1_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.117010"},{"key":"b2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.d01-1169.x"},{"key":"b3_3","doi-asserted-by":"publisher","DOI":"10.1080\/000155500300012873"},{"key":"b4_4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1996.d01-970.x"},{"key":"b5_5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1017\/CBO9780511545771.010","volume-title":"Atopic Dermatitis. The Epidemiology, Causes and Prevention of Atopic Eczema.","author":"Larsen FS","year":"2000"},{"key":"b6_6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2000.00698.x"},{"key":"b7_7","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.106484"},{"key":"b8_8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92473-2"},{"key":"b9_9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0091-6749(99)70536-1","volume":"103","author":"Williams H","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"b10_10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/CBO9780511545771.005","volume-title":"Atopic Dermatitis. The Epidemiology, Causes and Prevention of Atopic Eczema.","author":"Williams HC","year":"2000"},{"key":"b11_11","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1542\/peds.111.3.608","volume":"111","author":"Eichenfield LF","year":"2003","journal-title":"Pediatrics"},{"key":"b12_12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91556-1"},{"key":"b13_13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04283.x"},{"key":"b14_14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00128071-200203010-00005","volume":"3","author":"Brazzini B","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"b15_15","doi-asserted-by":"crossref","unstructured":"15 G Goerz, P Lehmann, T Ruzicka, J Ring, and B Przybilla . Topical treatment with corticosteroids . In: Handbook of Atopic Eczema (, 1991 : 375 -90 .","DOI":"10.1007\/978-3-662-02671-7_40"},{"key":"b16_16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03473.x"},{"key":"b17_17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/bmj.326.7403.1367","volume":"326","author":"Berth-Jones J","year":"2003","journal-title":"BMJ"},{"key":"b18_18","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.1.e2"},{"key":"b19_19","first-page":"185","volume-title":"Atopic Dermatitis: from Pathogenesis to Treatment (","author":"Boguniewicz M","year":"1996"},{"key":"b20_20","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","volume":"40","author":"Kino T","year":"1987","journal-title":"J Antibiot (Tokyo)"},{"key":"b21_21","first-page":"231","volume":"15","author":"Arai T","year":"1962","journal-title":"J Antibiotics, Series A"},{"key":"b22_22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/sder.2001.29066","volume":"20","author":"Stuetz A","year":"2001","journal-title":"Semin Cutan Med Surg"},{"key":"b23_23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1189\/jlb.71.1.9","volume":"71","author":"Almawi WY","year":"2002","journal-title":"J Leukoc Biol"},{"key":"b24_24","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1021\/bi00131a002","volume":"31","author":"Liu J","year":"1992","journal-title":"Biochemistry"},{"key":"b25_25","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02974.x"},{"key":"b26_26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00128071-200203060-00002","volume":"3","author":"Reitamo S","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"b27_27","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.112600"},{"key":"b28_28","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.112942"},{"key":"b29_29","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.4049\/jimmunol.146.7.2374","volume":"146","author":"de Paulis A","year":"1991","journal-title":"J Immunol"},{"key":"b30_30","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12614216"},{"key":"b31_31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/clin.1993.1130","volume":"68","author":"Hom JT","year":"1993","journal-title":"Clin Immunol Immunopathol"},{"key":"b32_32","doi-asserted-by":"publisher","DOI":"10.1006\/mcbr.1999.0108"},{"key":"b33_33","doi-asserted-by":"publisher","DOI":"10.1016\/S0192-0561(99)00076-4"},{"key":"b34_34","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05559.x"},{"key":"b35_35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.0022-202X.2004.22324.x","volume":"122","author":"Hoetzenecker W","year":"2004","journal-title":"J Invest Dermatol"},{"key":"b36_36","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2000.009003165.x"},{"key":"b37_37","unstructured":"37 A Billich, H Aschauer, and A Stuetz . Pimecrolimus (SDZ ASM 981) permeates less through skin than topical corticosteroids . 20th World Congress of Dermatology, Paris, France July, 2002 . Poster presentation."},{"key":"b38_38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0190-9622(98)70541-9","volume":"38","author":"Alaiti S","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"b39_39","unstructured":"39 NA Undre, A Green, and J Harper et al.Tacrolimus pharmacokinetics in paediatric patients with moderate to severe atopic dermatitis after single and repeated application . World Congress of Dermatology, Paris, France 1-5 July, 2002, P0273."},{"key":"b40_40","unstructured":"40 NA Undre, A Rubins, and R Gutmane et al.Pharmacokinetics of tacrolimus ointment in adult patients with moderate to severe atopic dermatitis . World Congress of Dermatology, Paris, France 1-5 July, 2002, P0274."},{"key":"b41_41","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1525-1470.1988.tb00904.x","volume":"5","author":"Turpeinen M","year":"1988","journal-title":"Pediatr Dermatol"},{"key":"b42_42","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/0190-9622(95)90288-0","volume":"33","author":"Aalto-Korte K","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"b43_43","first-page":"191","volume":"23","author":"Rico MJ","year":"2002","journal-title":"Allergy Asthma Proc"},{"key":"b44_44","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1067\/mai.2003.1492","volume":"111","author":"Eichenfield LF","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"b45_45","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.109810"},{"key":"b46_46","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.109817"},{"key":"b47_47","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.109813"},{"key":"b48_48","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.8.999"},{"key":"b49_49","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.109812"},{"key":"b50_50","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.121832"},{"key":"b51_51","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.121831"},{"key":"b52_52","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1046\/j.1365-2133.2004.05782.x","volume":"150","author":"Reitamo S","year":"2004","journal-title":"Br J Dermatol"},{"key":"b53_53","unstructured":"53 S Reitamo, and the European Tacrolimus Ointment Study Group. , 0. 1% Tacrolimus ointment is significantly more efficacious than a steroid regimen in adults with moderate to severe atopic dermatitis . 1st Spring Congress of the European Academy of Dermatology and Venereology, St. Julian's, Malta 27 February - 1 March, 2003 . Poster presentation PP1-28."},{"key":"b54_54","doi-asserted-by":"crossref","unstructured":"54 A Paller, J Hanifin, and L Eichenfield et al.Tacrolimus ointment monotherapy is a safe and effective treatment for atopic dermatitis long-term (more than 3 years) . American Academy of Dermatology 61st Annual Meeting, San Francisco, CA 21-26 March, 2003, P24.","DOI":"10.1016\/S0091-6749(03)80405-0"},{"key":"b55_55","unstructured":"55 JYM Koo, AB Fleischer, and D Pariser et al.Tacrolimus ointment 0.1% is safe and effective in the treatment for atopic dermatitis: final results of a large (over 7,000 patients) open-label study . American Academy of Dermatology 61st Annual Meeting, San Francisco, CA2003 Poster presentation P22."},{"key":"b56_56","unstructured":"56 W Abramovits, R Cornell, and B Chipps et al.Monotherapy with 0.03% tacrolimus ointment is a safe and effective treatment for atopic dermatitis . American Academy of Dermatology 61st Annual Meeting, San Francisco, CA 21-26 March, 2003, P201."},{"key":"b57_57","unstructured":"57 AB Fleischer, Controlling atopic dermatitis with ProtopicR- new insights . 12th Congress of the European Academy of Dermatology and Venereology, Barcelona, Spain 15-18 October, 2003 . Oral presentation."},{"key":"b58_58","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.122187"},{"key":"b59_59","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2003.65"},{"key":"b60_60","doi-asserted-by":"publisher","DOI":"10.1159\/000065863"},{"key":"b61_61","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.126500"},{"key":"b62_62","unstructured":"62 US Food and Drug Administration Center for Drug Evaluation and Research . Medical Officer's Review of New Drug Application 21-302 [Elidel (Pimecrolimus Cream) Approval Package Online]. Available at: http:\/\/www.fda.gov\/cder\/foi\/nda\/2001\/21-02_Elidel.htm."},{"key":"b63_63","unstructured":"63 S Kempers, M Boguniewicz, and E Carter et al.Comparison of pimecrolimus cream 1% and tacrolimus ointment 0.03% in paediatric patients with atopic eczema . 12th Congress of the European Academy of Dermatology and Venereology, Barcelona, Spain 15-18 October, 2003 ; P2 -41 ."},{"key":"b64_64","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2001.100102.x"},{"key":"b65_65","first-page":"13","volume":"144","author":"Rajka G","year":"1989","journal-title":"Acta Derm Venereol Suppl"},{"key":"b66_66","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1046\/j.1468-3083.2001.00224.x","volume":"15","author":"Ho V","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"b67_67","unstructured":"67 A Remitz, and for the European Tacrolimus Ointment Study Group. , Superior flare prevention with 0.1% tacrolimus ointment in adult patients with moderate to severe atopic dermatitis . Proceedings from the 11th Congress of the European Academy of Dermatology and Venereology, Prague, Czech Republic 2-6 October, 2002 ."},{"key":"b68_68","first-page":"5","volume":"14","author":"Kapp A","year":"2003","journal-title":"J Dermatolog Treat"},{"key":"b69_69","unstructured":"69 J Spergel, B Prenner, and MJ Rico . Tacrolimus ointment is a safe and effective treatment for mild atopic dermatitis . American Academy of Allergy, Asthma and Immunology 60th Annual Meeting, Denver, CO 7-12 March, 2003 ; P349."},{"key":"b70_70","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04134.x"},{"key":"b71_71","unstructured":"71 H Nakagawa, and the Japanese FK506 Ointment Study Group. , Comparative study of 0.1% FK506 (tacrolimus) ointment vs. 0.12% betamethasone valerate ointment in atopic dermatitis (trunk and extremities lesions) . Clin Dermatol 2000, Singapore June 18-20, 1998 ; 271."},{"key":"b72_72","first-page":"1266","volume":"16","author":"Nakagawa H","year":"1998","journal-title":"J Dermatol Sci"},{"key":"b73_73","first-page":"16","volume":"60","author":"Aly R","year":"1980","journal-title":"Acta Dermatovener (Stockholm)"},{"key":"b74_74","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2001.01279-9.x"},{"key":"b75_75","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.112131"},{"key":"b76_76","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0190-9622(86)70155-2","volume":"15","author":"Nilsson E","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"b77_77","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2133.1994.tb08556.x","volume":"131","author":"Stalder JF","year":"1994","journal-title":"Br J Dermatol"},{"key":"b78_78","unstructured":"78 Novartis Pharmaceutical Corp. ElidelR(pimecrolimus cream, 1%). East Hanover, NJ: Novartis Pharmaceutical Corp., December2001 (package insert)."},{"key":"b79_79","unstructured":"79 Fujisawa Healthcare. ProtopicR(Tacrolimus ointment, 0.03% and 0.1%). Summary of product characteristics.Deerfield, IL: Fujisawa Healthcare, April2002 ."},{"key":"b80_80","unstructured":"80 Novartis Pharmaceutical Corp.ElidelR(pimecrolimus cream, 1%).Summary of product characteristics. East Hanover, NJ: Novartis Pharmaceutical Corp., October2002 ."},{"key":"b81_81","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.124603"},{"key":"b82_82","volume-title":"ProtopicR (Tacrolimus Ointment, 0.03% and 0.1%).","author":"Fujisawa Healthcare.","year":"2000"},{"key":"b83_83","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.7.805"},{"key":"b84_84","first-page":"P2","volume":"15","author":"Van Leent EJM","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"b85_85","doi-asserted-by":"publisher","DOI":"10.1159\/000051813"},{"key":"b86_86","first-page":"109","volume":"15","author":"Harper J","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"b87_87","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04133.x"},{"key":"b88_88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709183371203"},{"key":"b89_89","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0091-6749(98)70281-7","volume":"102","author":"Boguniewicz M","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"b90_90","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00008480-200208000-00010","volume":"14","author":"Bernard LA","year":"2002","journal-title":"Curr Opin Pediatr"},{"key":"b91_91","first-page":"54","volume-title":"Handbook of Atopic Eczema","author":"Strannegard O","year":"1991"},{"key":"b92_92","unstructured":"92 ER Stiehm, RL Roberts, and MS Kaplan et al.Tacrolimus ointment does not alter immune responses of eczematous children . American Academy of Allergy, Asthma and Immunology 60th Annual Meeting, Denver, CO 7-12 March, 2003 ; 245 ."},{"key":"b93_93","unstructured":"93 Food and Drug Administration Center for Drug Evaluation and Research. Pharmacologist's Review of New Drug Application 50777 [Protopic (Tacrolimus Ointment) Approval Package Online]. Available at: http:\/\/www.fda.gov\/cder\/foi\/nda\/2000\/50777_Protopic.htm."},{"key":"b94_94","unstructured":"94 Food and Drug Administration Center for Drug Evaluation and Research. Pharmacologist's Review of New Drug Application 21-302 [Elidel (Pimecrolimus Cream) Approval Package Online]. Available at: http:\/\/www.fda.gov\/cder\/foi\/nda\/2001\/21302_Elidel.htm."},{"key":"b95_95","first-page":"138","volume":"16","author":"Rico MJ","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"b96_96","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/archderm.136.2.179","volume":"136","author":"Frieling UM","year":"2000","journal-title":"Arch Dermatol"},{"key":"b97_97","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000049394","volume":"15","author":"Korting HC","year":"2002","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"key":"b98_98","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1996.d01-934.x"},{"key":"b99_99","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00323.x"},{"key":"b100_100","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04076.x"},{"key":"b101_101","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/j.1365-2133.2004.06017.x","volume":"150","author":"Kyllonen H","year":"2004","journal-title":"Br J Dermatol"},{"key":"b102_102","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1017\/CBO9780511545771.008","volume-title":"Atopic Dermatitis. The Epidemiology, Causes and Prevention of Atopic Eczema.","author":"Herd RM","year":"2000"},{"key":"b103_103","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.240"},{"key":"b104_104","unstructured":"104 M Rustin, and on behalf of the UK Tacrolimus Ointment Study Panel , Pharmacoeconomics of 0.1% tacrolimus ointment in adults and children with moderate to severe atopic dermatitis . 2nd Spring Congress of the European Academy of Dermatology and Venereology, Budapest, Hungary, 29 April-1 May 2004. Poster presentation PS221."},{"key":"b105_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3111\/200306001014","volume":"6","author":"Abramovits W","year":"2003","journal-title":"J Med Economics"},{"key":"b106_106","unstructured":"106 National Institutes of Health, National Heart, Lung and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 2. Guidelines for the Diagnosis and Management of Asthma. Available at: http:\/\/www.ncbi.nlm.nih.gov\/books\/bv.fcgi?call=bv.View.ShowTOCrid=asthma.TOCdepth=2."},{"key":"b107_107","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-0536.1989.tb03135.x","volume":"20","author":"Dooms-Goossens A","year":"1989","journal-title":"Contact Dermatitis"},{"key":"b108_108","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2133.1992.tb14847.x","volume":"127","author":"Burden AD","year":"1992","journal-title":"Br J Dermatol"},{"key":"b109_109","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1600-0536.1996.tb02264.x","volume":"35","author":"Dooms-Goossens A","year":"1996","journal-title":"Contact Dermatitis"},{"key":"b110_110","first-page":"533","volume":"10","author":"Corazza M","year":"2000","journal-title":"Eur J Dermatol"},{"key":"b111_111","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0190-9622(93)70084-7","volume":"28","author":"Lauerma AI","year":"1993","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2004.06269.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2004.06269.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T08:34:42Z","timestamp":1682843682000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/151\/s70\/3\/6635525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":111,"journal-issue":{"issue":"s70","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1111\/j.1365-2133.2004.06269.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2004.06269.x","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}